Skip to main content

Table 3 Late toxicities in patients treated with cetuximab + CCRT versus CCRT

From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

Late toxicity

Cetuximab + CCRT

(n = 62)

CCRT

(n = 124)

P

Xerostomia*

11 (17.7%)

27 (21.8%)

0.52

Hearing loss*

13 (21.0%)

23 (18.5%)

0.694

Skin dystrophy

3 (4.8%)

5 (4.0%)

1

Neck fibrosis

6 (9.7%)

17 (13.7%)

0.431

Trismus

2 (3.2%)

11 (8.9%)

0.263

Radiation encephalopathy

1 (1.6%)

9 (7.3%)

0.108

Cranial nerve palsy

7 (11.3%)

9 (7.3%)

0.364

*Grade 2–4 toxicities

   
  1. *grade 2-4 toxicities